{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:43:12Z","timestamp":1790689392750,"version":"4.1.0"},"reference-count":233,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["EXPL\/BIA-BQM\/1361\/2021"],"award-info":[{"award-number":["EXPL\/BIA-BQM\/1361\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejmech.2024.116723","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T23:01:33Z","timestamp":1722380493000},"page":"116723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities"],"prefix":"10.1016","volume":"277","author":[{"given":"Ricardo","family":"Amorim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Chavarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Benfeito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Cagide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo J.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1050-2402","authenticated-orcid":false,"given":"Fernanda","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116723_bib1","first-page":"715","article-title":"Non-alcoholic fatty liver disease: an expanded review","volume":"9","author":"Benedict","year":"2017"},{"key":"10.1016\/j.ejmech.2024.116723_bib2","first-page":"167","volume":"14","author":"Akter","year":"2022"},{"issue":"4","key":"10.1016\/j.ejmech.2024.116723_bib3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2024.116723_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101122","article-title":"Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans","volume":"50","author":"Pafili","year":"2021","journal-title":"Mol. Metabol."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12072-020-10121-2","article-title":"How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?","volume":"15","author":"Geng","year":"2021","journal-title":"Hepatol Int"},{"issue":"36","key":"10.1016\/j.ejmech.2024.116723_bib6","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.3748\/wjg.v23.i36.6571","article-title":"Nonalcoholic fatty liver disease: evolving paradigms","volume":"23","author":"Lonardo","year":"2017","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116723_bib7","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.ejmech.2024.116723_bib8","doi-asserted-by":"crossref","first-page":"8591","DOI":"10.3390\/ijms15058591","article-title":"Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation","volume":"15","author":"Peverill","year":"2014","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib9","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1172\/JCI34275","article-title":"Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice","volume":"118","author":"Postic","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metabol."},{"issue":"10","key":"10.1016\/j.ejmech.2024.116723_bib11","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.tem.2015.07.006","article-title":"Ceramides - lipotoxic inducers of metabolic disorders","volume":"26","author":"Chaurasia","year":"2015","journal-title":"Trends Endocrinol. Metabol."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116723_bib12","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ejmech.2024.116723_bib13","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ejmech.2024.116723_bib14","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116723_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12071166","article-title":"Combination therapies for nonalcoholic fatty liver disease","volume":"12","author":"Makri","year":"2022","journal-title":"J. Personalized Med."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116723_bib16","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116723_bib17","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116723_bib18","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116723_bib19","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.ejmech.2024.116723_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann. Intern. Med."},{"issue":"18","key":"10.1016\/j.ejmech.2024.116723_bib21","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib23","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2174\/1570161115666170621082910","article-title":"Statins: an under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk","volume":"16","author":"Athyros","year":"2018","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116723_bib24","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1210\/jc.2017-00867","article-title":"Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post hoc analysis of a randomized trial","volume":"102","author":"Bril","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116723_bib25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/13543784.2021.1951701","article-title":"Anti-diabetic drugs and NASH: from current options to promising perspectives","volume":"30","author":"Smati","year":"2021","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2024.116723_bib26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metabol."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/hepr.12351","article-title":"Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)","volume":"45","author":"Eguchi","year":"2015","journal-title":"Hepatol. Res."},{"issue":"10019","key":"10.1016\/j.ejmech.2024.116723_bib28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"10019","key":"10.1016\/j.ejmech.2024.116723_bib29","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ejmech.2024.116723_bib30","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116723_bib31","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1056\/NEJMc1615712","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"376","author":"Ipp","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116723_bib32","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.ejmech.2024.116723_bib33","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1046\/j.1365-2036.2001.01083.x","article-title":"Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study","volume":"15","author":"Hasegawa","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"7\u20138","key":"10.1016\/j.ejmech.2024.116723_bib34","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.nut.2014.11.018","article-title":"Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"31","author":"Sato","year":"2015","journal-title":"Nutrition"},{"issue":"126","key":"10.1016\/j.ejmech.2024.116723_bib35","first-page":"1445","article-title":"Long-term (>=2 yr) efficacy of vitamin E for non-alcoholic steatohepatitis","volume":"60","author":"Sumida","year":"2013","journal-title":"Hepato-Gastroenterology"},{"issue":"10","key":"10.1016\/j.ejmech.2024.116723_bib36","article-title":"Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ejmech.2024.116723_bib37","doi-asserted-by":"crossref","first-page":"G724","DOI":"10.1152\/ajpgi.00063.2016","article-title":"Statins improve NASH via inhibition of RhoA and Ras","volume":"311","author":"Schierwagen","year":"2016","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116723_bib38","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/hep.21848","article-title":"Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial","volume":"46","author":"Lewis","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.116723_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/1179552218787502","article-title":"An evidence-based review of statin use in patients with nonalcoholic fatty liver disease","volume":"11","author":"Sigler","year":"2018","journal-title":"Clin. Med. Insights Gastroenterol."},{"issue":"25","key":"10.1016\/j.ejmech.2024.116723_bib40","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.3748\/wjg.v21.i25.7860","article-title":"Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome","volume":"21","author":"Kargiotis","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1677\/joe.1.07066","article-title":"Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats","volume":"193","author":"Villicev","year":"2007","journal-title":"J. Endocrinol."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116723_bib42","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrd2830","article-title":"Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes","volume":"8","author":"Baxter","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116723_bib43","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1152\/physrev.00030.2013","article-title":"Thyroid hormone regulation of metabolism","volume":"94","author":"Mullur","year":"2014","journal-title":"Physiol. Rev."},{"issue":"10","key":"10.1016\/j.ejmech.2024.116723_bib44","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/jm4019299","article-title":"A Highly Selective Thyroid Hormone Receptor \u03b2 agonist in clinical trials for the treatment of dyslipidemia","volume":"57","author":"Kelly","year":"2014","journal-title":"J. Med. Chem."},{"issue":"10213","key":"10.1016\/j.ejmech.2024.116723_bib45","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejmech.2024.116723_bib46","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116723_bib47","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116723_bib48","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0168-8278(99)80243-8","article-title":"A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis","volume":"31","author":"Basaranoglu","year":"1999","journal-title":"J. Hepatol."},{"issue":"17","key":"10.1016\/j.ejmech.2024.116723_bib49","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1001\/jama.1984.03340410049031","article-title":"Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man","volume":"251","author":"Kes\u00e4niemi","year":"1984","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ejmech.2024.116723_bib50","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s11096-011-9550-x","article-title":"Gemfibrozil hepatotoxicity: a case report","volume":"33","author":"Dom\u00ednguez Tordera","year":"2011","journal-title":"Int. J. Clin. Pharm."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib51","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.dld.2007.10.002","article-title":"A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease","volume":"40","author":"Fern\u00e1ndez-Miranda","year":"2008","journal-title":"Dig. Liver Dis."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116723_bib52","first-page":"1464","article-title":"Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study","volume":"23","author":"Laurin","year":"1996","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ihj.2015.02.007","article-title":"Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients","volume":"67","author":"Shetty","year":"2015","journal-title":"Indian Heart J."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116723_bib54","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ejmech.2024.116723_bib55","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study","volume":"72","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116723_bib56","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejmech.2024.116723_bib57","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.ejmech.2024.116723_bib58","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1136\/annrheumdis-2015-208029","article-title":"Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis","volume":"75","author":"Ruzehaji","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2024.116723_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106170","article-title":"A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study","volume":"98","author":"Sven","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.ejmech.2024.116723_bib60","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","article-title":"Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial","volume":"249","author":"Ishibashi","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejmech.2024.116723_bib61","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3920196","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Tanase","year":"2020","journal-title":"J. Diabetes Res."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116723_bib62","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib63","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1758-5996-5-6","article-title":"Metformin: an old but still the best treatment for type 2 diabetes","volume":"5","author":"Rojas","year":"2013","journal-title":"Diabetol. Metab. Syndrome"},{"issue":"9","key":"10.1016\/j.ejmech.2024.116723_bib64","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.3390\/ijms22095016","article-title":"Metformin actions on the liver: protection mechanisms emerging in hepatocytes and immune cells against NASH-related HCC","volume":"22","author":"Zhang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116723_bib65","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13098-019-0491-1","article-title":"Long-term treatment with metformin in the prevention of fatty liver in Zucker diabetic fatty rats","volume":"11","author":"Sui","year":"2019","journal-title":"Diabetol. Metab. Syndrome"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116723_bib66","doi-asserted-by":"crossref","first-page":"827","DOI":"10.5009\/gnl20367","article-title":"Effects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: insights from the cellular to patient levels","volume":"15","author":"Pinyopornpanish","year":"2021","journal-title":"Gut and liver"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib67","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2036.2004.02025.x","article-title":"Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial","volume":"20","author":"Nair","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116723_bib68","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/00365520902845268","article-title":"Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial","volume":"44","author":"Haukeland","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116723_bib69","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S2468-1253(21)00300-9","article-title":"Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study","volume":"6","author":"Cusi","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.ejmech.2024.116723_bib70","article-title":"Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: a phase 1b study","volume":"2","author":"Fouqueray","year":"2021","journal-title":"Cell Rep Med"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116723_bib71","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10295","key":"10.1016\/j.ejmech.2024.116723_bib72","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116723_bib73","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10300","key":"10.1016\/j.ejmech.2024.116723_bib74","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.116723_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155248","article-title":"Recent guidelines for non-alcoholic fatty liver disease (NAFLD)\/fatty liver disease (FLD): are they already outdated and in need of supplementation?","volume":"136","author":"Valenzuela-Vallejo","year":"2022","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116723_bib76","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151511","article-title":"Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction","volume":"11","author":"Komiya","year":"2016","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.ejmech.2024.116723_bib78","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.2169\/internalmedicine.8754-16","article-title":"The improvement of the hepatic histological findings in a patient with non-alcoholic steatohepatitis with type 2 diabetes after the administration of the sodium-glucose cotransporter 2 inhibitor ipragliflozin","volume":"56","author":"Takeda","year":"2017","journal-title":"Intern. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib79","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/jcm9010259","article-title":"Ipragliflozin additively ameliorates non-alcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: a 24-week randomized controlled trial","volume":"9","author":"Han","year":"2020","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib80","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep4.1019","article-title":"Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies","volume":"1","author":"Akuta","year":"2017","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib81","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jgh3.12274","article-title":"Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes","volume":"4","author":"Marjot","year":"2020","journal-title":"JGH Open"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116723_bib82","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig. Dis. Sci."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116723_bib83","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3390\/ph15121516","article-title":"The impact of an SGLT2 inhibitor versus ursodeoxycholic acid on liver steatosis in diabetic patients","volume":"15","author":"Elhini","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib84","first-page":"729","article-title":"Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism","volume":"5","author":"Miyazaki","year":"2012","journal-title":"Mol. Med. Rep."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116723_bib85","doi-asserted-by":"crossref","first-page":"467","DOI":"10.5551\/jat.40873","article-title":"Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes","volume":"25","author":"Sugiyama","year":"2018","journal-title":"J. Atherosclerosis Thromb."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib86","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1060028020935105","article-title":"A systematic review of newer antidiabetic agents in the treatment of nonalcoholic fatty liver disease","volume":"55","author":"Dougherty","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.116723_bib87","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13098-020-00533-3","article-title":"Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes","volume":"12","author":"Hattori","year":"2020","journal-title":"Diabetol. Metab. Syndrome"},{"key":"10.1016\/j.ejmech.2024.116723_bib88","article-title":"Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116723_bib89","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1055\/a-1186-0841","article-title":"Effects and safety of sitagliptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"52","author":"Zhang","year":"2020","journal-title":"Horm. Metab. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib90","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1590\/1806-9282.65.1.33","article-title":"The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data","volume":"65","author":"Li","year":"2019","journal-title":"Rev. Assoc. Med. Bras."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116723_bib91","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3892\/br.2016.569","article-title":"Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes","volume":"4","author":"Mashitani","year":"2016","journal-title":"Biomed Rep"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116723_bib92","first-page":"1396","article-title":"Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease","volume":"32","author":"Hussain","year":"2016","journal-title":"Pakistan J. Med. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib93","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116723_bib94","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.gastro.2014.04.046","article-title":"No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial","volume":"147","author":"Sanyal","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ejmech.2024.116723_bib95","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/hep.27289","article-title":"Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study","volume":"60","author":"Scorletti","year":"2014","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116723_bib96","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"issue":"13","key":"10.1016\/j.ejmech.2024.116723_bib97","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/hepr.12887","article-title":"Ezetimibe for the treatment of non-alcoholic fatty liver disease: a meta-analysis","volume":"47","author":"Nakade","year":"2017","journal-title":"Hepatol. Res."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116723_bib98","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","article-title":"Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)","volume":"61","author":"Loomba","year":"2015","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.ejmech.2024.116723_bib99","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s11745-001-0824-3","article-title":"Arachidyl amido cholanoic acid (Aramchol) is a cholesterol solubilizer and prevents the formation of cholesterol gallstones in inbred mice","volume":"36","author":"Gilat","year":"2001","journal-title":"Lipids"},{"issue":"34","key":"10.1016\/j.ejmech.2024.116723_bib100","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.3748\/wjg.v26.i34.5101","article-title":"Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis via AMPK and mTOR regulation","volume":"26","author":"Fern\u00e1ndez-Ramos","year":"2020","journal-title":"World J. Gastroenterol."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116723_bib101","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cgh.2014.04.038","article-title":"The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease","volume":"12","author":"Safadi","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116723_bib102","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1172\/JCI63967","article-title":"Malonyl-CoA: the regulator of fatty acid synthesis and oxidation","volume":"122","author":"Foster","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116723_bib103","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.ejmech.2024.116723_bib104","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.cgh.2018.04.042","article-title":"Acetyl-CoA carboxylase inhibitor GS-0976 for 12 Weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis","volume":"16","author":"Lawitz","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"16","key":"10.1016\/j.ejmech.2024.116723_bib105","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.016334","article-title":"Effects of Epeleuton, a novel synthetic second-generation n-3 fatty acid, on non-alcoholic fatty liver disease, triglycerides, glycemic control, and cardiometabolic and inflammatory markers","volume":"9","author":"Climax","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116723_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12070647","article-title":"Farnesoid X receptor, bile acid metabolism, and gut microbiota","volume":"12","author":"Mori","year":"2022","journal-title":"Metabolites"},{"issue":"17","key":"10.1016\/j.ejmech.2024.116723_bib107","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib108","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"issue":"9972","key":"10.1016\/j.ejmech.2024.116723_bib109","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib110","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J. Hepatol."},{"issue":"17","key":"10.1016\/j.ejmech.2024.116723_bib111","doi-asserted-by":"crossref","first-page":"11761","DOI":"10.1074\/jbc.M112.446575","article-title":"Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease","volume":"288","author":"McMahan","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib112","doi-asserted-by":"crossref","first-page":"9196","DOI":"10.1038\/s41598-021-88493-0","article-title":"Discovery, optimization, and evaluation of non-bile acid FXR\/TGR5 dual agonists","volume":"11","author":"Miyata","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib113","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116723_bib114","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib115","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib116","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib117","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2165\/00003495-198734010-00003","article-title":"Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy","volume":"34","author":"Ward","year":"1987","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.ejmech.2024.116723_bib118","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/hep.24544","article-title":"Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial","volume":"54","author":"Zein","year":"2011","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116723_bib119","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3748\/wjg.v20.i2.569","article-title":"Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis","volume":"20","author":"Du","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116723_bib120","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1002\/hep4.2100","article-title":"Rencofilstat, a cyclophilin inhibitor: a phase 2a, multicenter, single-blind, placebo-controlled study in F2\/F3 NASH","volume":"6","author":"Harrison","year":"2022","journal-title":"Hepatol Commun"},{"issue":"8","key":"10.1016\/j.ejmech.2024.116723_bib121","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00535-018-1451-5","article-title":"To die or not to die: death signaling in nonalcoholic fatty liver disease","volume":"53","author":"Akazawa","year":"2018","journal-title":"J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.ejmech.2024.116723_bib122","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201810124","article-title":"Liver ASK1 protects from non-alcoholic fatty liver disease and fibrosis","volume":"11","author":"Challa","year":"2019","journal-title":"EMBO Mol. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib123","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jhep.2013.03.033","article-title":"Decoding cell death signals in liver inflammation","volume":"59","author":"Brenner","year":"2013","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116723_bib124","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib126","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/liv.12570","article-title":"The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis","volume":"35","author":"Barreyro","year":"2015","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib127","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/apt.15030","article-title":"Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3\/7 activation in subjects with non-alcoholic fatty liver disease","volume":"49","author":"Shiffman","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116723_bib128","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","article-title":"A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis","volume":"72","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116723_bib129","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jhep.2019.12.010","article-title":"Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension","volume":"72","author":"Garcia-Tsao","year":"2020","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116723_bib130","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.ejmech.2024.116723_bib131","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib132","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.116723_bib133","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2023.04.003","article-title":"Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study","volume":"22","author":"Anstee","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib134","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1892265","article-title":"Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity","volume":"10","author":"Sturgill","year":"2021","journal-title":"OncoImmunology"},{"issue":"11\u201312","key":"10.1016\/j.ejmech.2024.116723_bib135","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/apt.13816","article-title":"Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis","volume":"44","author":"Harrison","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116723_bib136","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2024.116723_bib137","first-page":"30","article-title":"Roles of FGFs as paracrine or endocrine signals in liver development, health, and disease","volume":"4","author":"Itoh","year":"2016","journal-title":"Front. Cell Dev. Biol."},{"issue":"10165","key":"10.1016\/j.ejmech.2024.116723_bib138","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.116723_bib139","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cgh.2023.04.011","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (falcon 1): a randomized phase 2b study","volume":"22","author":"Loomba","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2024.116723_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106335","article-title":"The FALCON program: two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis","volume":"104","author":"Abdelmalek","year":"2021","journal-title":"Contemp. Clin. Trials"},{"issue":"11","key":"10.1016\/j.ejmech.2024.116723_bib141","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116723_bib142","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/liv.14802","article-title":"Fibroblast Growth Factor 19: potential modulation of hepatic metabolism for the treatment of non-alcoholic fatty liver disease","volume":"41","author":"Sciarrillo","year":"2021","journal-title":"Liver Int."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116723_bib143","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 improves liver fibrosis and histology in 12 Weeks in patients with nonalcoholic steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib144","article-title":"Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases","volume":"3","author":"Sanyal","year":"2021","journal-title":"JHEP Rep"},{"issue":"8","key":"10.1016\/j.ejmech.2024.116723_bib145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20081948","article-title":"Pathophysiological, molecular and therapeutic issues of nonalcoholic fatty liver disease: an overview","volume":"20","author":"Marchisello","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116723_bib146","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.cgh.2017.04.016","article-title":"A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis","volume":"15","author":"Wah Kheong","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2024.116723_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2020.111092","article-title":"Impact of Silymarin in individuals with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"83","author":"Kalopitas","year":"2021","journal-title":"Nutrition"},{"issue":"10","key":"10.1016\/j.ejmech.2024.116723_bib148","article-title":"Silymarin in combination with vitamin C, vitamin E, coenzyme Q10 and selenomethionine to improve liver enzymes and blood lipid profile in NAFLD patients","volume":"56","author":"Curcio","year":"2020","journal-title":"Medicina (Kaunas)"},{"issue":"16","key":"10.1016\/j.ejmech.2024.116723_bib149","first-page":"3118","article-title":"Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study","volume":"19","author":"Aller","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2024.116723_bib150","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8742075","article-title":"Evaluation of the effect derived from silybin with vitamin D and vitamin E administration on clinical, metabolic, endothelial dysfunction, oxidative stress parameters, and serological worsening markers in nonalcoholic fatty liver disease patients","volume":"2019","author":"Federico","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116723_bib151","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221683","article-title":"Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: a randomized, double-blind, placebo controlled trial","volume":"14","author":"Navarro","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2024.116723_bib152","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-230X-8-40","article-title":"Resveratrol inhibits nonalcoholic fatty liver disease in rats","volume":"8","author":"Bujanda","year":"2008","journal-title":"BMC Gastroenterol."},{"issue":"10","key":"10.1016\/j.ejmech.2024.116723_bib153","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.nutres.2014.09.005","article-title":"Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease","volume":"34","author":"Faghihzadeh","year":"2014","journal-title":"Nutr. Res."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116723_bib154","doi-asserted-by":"crossref","first-page":"307","DOI":"10.15171\/apb.2018.036","article-title":"Effects of pharmacologic dose of resveratrol supplementation on oxidative\/antioxidative status biomarkers in nonalcoholic fatty liver disease patients: a randomized, double-blind, placebo-controlled trial","volume":"8","author":"Asghari","year":"2018","journal-title":"Adv. Pharmaceut. Bull."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib155","doi-asserted-by":"crossref","first-page":"59","DOI":"10.15403\/jgld.2014.1121.261.ely","article-title":"Resveratrol supplementation in patients with non-alcoholic fatty liver disease: systematic review and meta-analysis","volume":"26","author":"Elgebaly","year":"2017","journal-title":"J Gastrointestin Liver Dis"},{"issue":"8","key":"10.1016\/j.ejmech.2024.116723_bib156","doi-asserted-by":"crossref","DOI":"10.3390\/nu12082435","article-title":"Effects of resveratrol supplementation in patients with non-alcoholic fatty liver disease-A meta-analysis","volume":"12","author":"Jakubczyk","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.ejmech.2024.116723_bib157","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-3-030-64872-5_3","article-title":"The effect of curcumin phytosome on the treatment of patients with non-alcoholic fatty liver disease: a double-blind, randomized, placebo-controlled trial","volume":"1308","author":"Mirhafez","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"issue":"38","key":"10.1016\/j.ejmech.2024.116723_bib158","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.3748\/wjg.v26.i38.5812","article-title":"Is vitamin D receptor a druggable target for non-alcoholic steatohepatitis?","volume":"26","author":"Cao","year":"2020","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib159","doi-asserted-by":"crossref","first-page":"527","DOI":"10.21873\/anticanres.13981","article-title":"Vitamin D in preclinical models of fatty liver disease","volume":"40","author":"Karatayli","year":"2020","journal-title":"Anticancer Res."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116723_bib160","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1074\/jbc.RA119.011487","article-title":"Vitamin D receptor targets hepatocyte nuclear factor 4\u03b1 and mediates protective effects of vitamin D in nonalcoholic fatty liver disease","volume":"295","author":"Zhang","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib161","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4254\/wjh.v10.i1.142","article-title":"Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: a PRISMA compliant systematic review and meta-analysis of pooled data","volume":"10","author":"Saberi","year":"2018","journal-title":"World J. Hepatol."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116723_bib162","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.dld.2017.02.003","article-title":"Vitamin D and histologic severity of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"49","author":"Jaruvongvanich","year":"2017","journal-title":"Dig. Liver Dis. : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116723_bib163","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/jgh3.12010","article-title":"Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"1","author":"Sakpal","year":"2017","journal-title":"JGH open : an open access journal of gastroenterology and hepatology"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116723_bib164","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.clnu.2016.09.020","article-title":"Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial","volume":"36","author":"Lorvand Amiri","year":"2017","journal-title":"Clin. Nutr."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116723_bib165","first-page":"631","article-title":"Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial","volume":"19","author":"Lorvand Amiri","year":"2016","journal-title":"Arch. Iran. Med."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116723_bib166","first-page":"969","article-title":"Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver","volume":"5","author":"Foroughi","year":"2014","journal-title":"Int. J. Prev. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib167","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12020-014-0336-5","article-title":"Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial","volume":"47","author":"Sharifi","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.ejmech.2024.116723_bib168","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12916-016-0638-y","article-title":"No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial","volume":"14","author":"Barchetta","year":"2016","journal-title":"BMC Med."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116723_bib169","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1080\/00365521.2018.1501091","article-title":"Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study","volume":"53","author":"Geier","year":"2018","journal-title":"Scand. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116723_bib170","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.dsx.2018.03.006","article-title":"Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial","volume":"12","author":"Dabbaghmanesh","year":"2018","journal-title":"Diabetes Metabol. Syndr."},{"issue":"16","key":"10.1016\/j.ejmech.2024.116723_bib171","first-page":"7607","article-title":"A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin","volume":"27","author":"Alarfaj","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116723_bib172","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00431-021-04262-1","article-title":"Vitamin D and nonalcoholic fatty liver disease in children: a randomized controlled clinical trial","volume":"181","author":"El Amrousy","year":"2022","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ejmech.2024.116723_bib173","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/736837","article-title":"Glutathione homeostasis and functions: potential targets for medical interventions","volume":"2012","author":"Lushchak","year":"2012","journal-title":"J. Amino Acids"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib174","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12876-017-0652-3","article-title":"Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study","volume":"17","author":"Honda","year":"2017","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.ejmech.2024.116723_bib175","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12967-016-0982-x","article-title":"Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease","volume":"14","author":"Chang","year":"2016","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib176","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1038\/s41467-021-25701-5","article-title":"A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes","volume":"12","author":"Harrison","year":"2021","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116723_bib177","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1476-5381.2011.01397.x","article-title":"The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings","volume":"163","author":"Mallat","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib178","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10030393","article-title":"Phytocannabinoids-A green approach toward non-alcoholic fatty liver disease treatment","volume":"10","author":"Berk","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2024.116723_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107477","article-title":"The therapeutic potential of second and third generation CB1R antagonists","volume":"208","author":"Cinar","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116723_bib180","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1021\/acsptsci.0c00213","article-title":"Peripherally selective CB1 receptor antagonist improves symptoms of metabolic syndrome in mice","volume":"4","author":"Khan","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116723_bib181","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/hep.24524","article-title":"Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice","volume":"54","author":"Louvet","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.116723_bib182","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101087","article-title":"Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53\/miRNA-22\/SIRT1\/PPAR\u03b1 dependent","volume":"42","author":"Azar","year":"2020","journal-title":"Mol. Metabol."},{"issue":"11\u201312","key":"10.1016\/j.ejmech.2024.116723_bib183","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/apt.16664","article-title":"Randomised clinical trial: a phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis","volume":"54","author":"Safadi","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"17","key":"10.1016\/j.ejmech.2024.116723_bib184","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116723_bib185","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.atherosclerosis.2011.10.029","article-title":"Effects of the PPAR-\u03b4 agonist MBX-8025 on atherogenic dyslipidemia","volume":"220","author":"Choi","year":"2012","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib186","doi-asserted-by":"crossref","first-page":"188","DOI":"10.33160\/yam.2020.08.009","article-title":"Pemafibrate dramatically ameliorated the values of liver function tests and fibrosis marker in patients with non-alcoholic fatty liver disease","volume":"63","author":"Ikeda","year":"2020","journal-title":"Yonago Acta Med."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib187","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","volume":"6","author":"Takahashi","year":"2022","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib188","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13098-021-00644-5","article-title":"Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis","volume":"13","author":"Hattori","year":"2021","journal-title":"Diabetol. Metab. Syndrome"},{"issue":"8","key":"10.1016\/j.ejmech.2024.116723_bib189","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/ejcn.2017.9","article-title":"Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study","volume":"71","author":"Hodson","year":"2017","journal-title":"Eur. J. Clin. Nutr."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116723_bib190","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.ejmech.2024.116723_bib191","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083481","article-title":"Therapy of experimental NASH and fibrosis with galectin inhibitors","volume":"8","author":"Traber","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ejmech.2024.116723_bib192","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/ptr.5659","article-title":"Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial","volume":"30","author":"Rahmani","year":"2016","journal-title":"Phytother Res."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116723_bib193","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134172","article-title":"Efficacy of berberine in patients with non-alcoholic fatty liver disease","volume":"10","author":"Yan","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ejmech.2024.116723_bib194","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.bmc.2014.02.053","article-title":"Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR)","volume":"22","author":"Merk","year":"2014","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib195","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s42004-020-00411-z","article-title":"A triple farnesoid X receptor and peroxisome proliferator-activated receptor \u03b1\/\u03b4 activator reverses hepatic fibrosis in diet-induced NASH in mice","volume":"3","author":"Heitel","year":"2020","journal-title":"Commun. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib196","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1021\/acs.jmedchem.5b01239","article-title":"N-benzylbenzamides: a novel merged scaffold for orally available dual soluble epoxide hydrolase\/peroxisome proliferator-activated receptor \u03b3 modulators","volume":"59","author":"Bl\u00f6cher","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116723_bib197","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bcp.2019.05.023","article-title":"A dual farnesoid X receptor\/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice","volume":"166","author":"Hye Khan","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib198","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/cmdc.201900576","article-title":"Dual farnesoid X receptor\/soluble epoxide hydrolase modulators derived from zafirlukast","volume":"15","author":"Schierle","year":"2020","journal-title":"ChemMedChem"},{"issue":"15","key":"10.1016\/j.ejmech.2024.116723_bib199","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/cmdc.202100118","article-title":"Development and in vitro profiling of dual FXR\/LTA4H modulators","volume":"16","author":"Schierle","year":"2021","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib200","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1124\/jpet.118.255216","article-title":"RLA8-A new and highly effective quadruple PPAR-\u03b1\/\u03b3\/\u03b4 and GPR40 agonist to reverse nonalcoholic steatohepatitis and fibrosis","volume":"369","author":"Li","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2024.116723_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114061","article-title":"Discovery of new and highly effective quadruple FFA1 and PPAR\u03b1\/\u03b3\/\u03b4 agonists as potential anti-fatty liver agents","volume":"229","author":"Zhou","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116723_bib202","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1146\/annurev.pharmtox.47.120505.105110","article-title":"Targeting antioxidants to mitochondria by conjugation to lipophilic cations","volume":"47","author":"Murphy","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116723_bib203","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tips.2012.03.010","article-title":"Mitochondrial pharmacology","volume":"33","author":"Smith","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116723_bib204","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s10541-005-0104-5","article-title":"Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology","volume":"70","author":"Ross","year":"2005","journal-title":"Biochemistry (Mosc)."},{"issue":"15","key":"10.1016\/j.ejmech.2024.116723_bib205","doi-asserted-by":"crossref","first-page":"10043","DOI":"10.1021\/acs.chemrev.7b00042","article-title":"Mitochondria-targeted triphenylphosphonium-based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications","volume":"117","author":"Zielonka","year":"2017","journal-title":"Chem. Rev."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116723_bib206","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1042\/BST20160108","article-title":"Understanding and preventing mitochondrial oxidative damage","volume":"44","author":"Murphy","year":"2016","journal-title":"Biochem. Soc. Trans."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib207","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/hep.24377","article-title":"Mitochondria-targeted ubiquinone (MitoQ) decreases ethanol-dependent micro and macro hepatosteatosis","volume":"54","author":"Chacko","year":"2011","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.ejmech.2024.116723_bib208","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.bbabio.2015.05.019","article-title":"The mitochondrial-targeted antioxidant, MitoQ, increases liver mitochondrial cardiolipin content in obesogenic diet-fed rats","volume":"1847","author":"Fouret","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"5","key":"10.1016\/j.ejmech.2024.116723_bib209","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.freeradbiomed.2011.11.026","article-title":"The mitochondria-targeted antioxidant MitoQ decreases features of the metabolic syndrome in ATM+\/-\/ApoE-\/- mice","volume":"52","author":"Mercer","year":"2012","journal-title":"Free Radic. Biol. Med."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116723_bib210","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1478-3231.2010.02250.x","article-title":"The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients","volume":"30","author":"Gane","year":"2010","journal-title":"Liver Int."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116723_bib211","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.freeradbiomed.2007.12.036","article-title":"A mitochondria-targeted nitroxide is reduced to its hydroxylamine by ubiquinol in mitochondria","volume":"44","author":"Trnka","year":"2008","journal-title":"Free Radic. Biol. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116723_bib212","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1159\/000335802","article-title":"Mitochondria-targeted antioxidants protect pancreatic \u03b2-cells against oxidative stress and improve insulin secretion in glucotoxicity and glucolipotoxicity","volume":"28","author":"Lim","year":"2011","journal-title":"Cell. Physiol. Biochem."},{"issue":"10","key":"10.1016\/j.ejmech.2024.116723_bib213","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.freeradbiomed.2010.08.018","article-title":"SOD1 and MitoTEMPO partially prevent mitochondrial permeability transition pore opening, necrosis, and mitochondrial apoptosis after ATP depletion recovery","volume":"49","author":"Liang","year":"2010","journal-title":"Free Radic. Biol. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116723_bib214","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1161\/ATVBAHA.111.241802","article-title":"Resolution of mitochondrial oxidative stress rescues coronary collateral growth in Zucker obese fatty rats","volume":"32","author":"Pung","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2024.116723_bib215","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9329427","article-title":"Protective effects of MitoTEMPO on nonalcoholic fatty liver disease via regulating myeloid-derived suppressor cells and inflammation in mice","volume":"2020","author":"Wu","year":"2020","journal-title":"BioMed Res. Int."},{"issue":"16","key":"10.1016\/j.ejmech.2024.116723_bib216","doi-asserted-by":"crossref","first-page":"7084","DOI":"10.1021\/acs.jmedchem.7b00741","article-title":"Development of a mitochondriotropic antioxidant based on caffeic acid: proof of concept on cellular and mitochondrial oxidative stress models","volume":"60","author":"Teixeira","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116723_bib217","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.freeradbiomed.2021.12.304","article-title":"Mitochondriotropic antioxidant based on caffeic acid AntiOxCIN4 activates Nrf2-dependent antioxidant defenses and quality control mechanisms to antagonize oxidative stress-induced cell damage","volume":"179","author":"Amorim","year":"2022","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2024.116723_bib218","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102400","article-title":"Mitochondria-targeted anti-oxidant AntiOxCIN4 improved liver steatosis in Western diet-fed mice by preventing lipid accumulation due to upregulation of fatty acid oxidation, quality control mechanism and antioxidant defense systems","volume":"55","author":"Amorim","year":"2022","journal-title":"Redox Biol."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116723_bib219","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/jphp.13273","article-title":"Drug repositioning: a brief overview","volume":"72","author":"Jourdan","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116723_bib220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114239","article-title":"Drug repositioning: progress and challenges in drug discovery for various diseases","volume":"234","author":"Hua","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"15","key":"10.1016\/j.ejmech.2024.116723_bib221","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.3748\/wjg.v25.i15.1783","article-title":"Repurposing drugs to target nonalcoholic steatohepatitis","volume":"25","author":"Sookoian","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2024.116723_bib222","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejps.2018.05.018","article-title":"Novel therapeutic drug identification and gene correlation for fatty liver disease using high-content screening: proof of concept","volume":"121","author":"Luo","year":"2018","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116723_bib223","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.103890","article-title":"A network-based computational and experimental framework for repurposing compounds toward the treatment of non-alcoholic fatty liver disease","volume":"25","author":"Zareifi","year":"2022","journal-title":"iScience"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116723_bib224","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/bab.2123","article-title":"An insight into the role of telmisartan as PPAR-\u03b3\/\u03b1 dual activator in the management of nonalcoholic fatty liver disease","volume":"69","author":"Devan","year":"2022","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.ejmech.2024.116723_bib225","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2147\/DMSO.S187092","article-title":"Telmisartan is effective to ameliorate metabolic syndrome in rat model - a preclinical report","volume":"11","author":"Cheng","year":"2018","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116723_bib226","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jacl.2019.10.006","article-title":"Niacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug?","volume":"13","author":"Kashyap","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.ejmech.2024.116723_bib227","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1194\/jlr.P023614","article-title":"Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients","volume":"53","author":"Hu","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejmech.2024.116723_bib228","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.freeradbiomed.2019.04.030","article-title":"Repositioning of niclosamide ethanolamine (NEN), an anthelmintic drug, for the treatment of lipotoxicity","volume":"137","author":"Park","year":"2019","journal-title":"Free Radic. Biol. Med."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116723_bib229","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/nm.3699","article-title":"Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice","volume":"20","author":"Tao","year":"2014","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.ejmech.2024.116723_bib230","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1210\/en.2013-2160","article-title":"Protection against high-fat diet-induced obesity in Helz2-deficient male mice due to enhanced expression of hepatic leptin receptor","volume":"155","author":"Yoshino","year":"2014","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib231","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70689-5","article-title":"Administration of small-molecule guanabenz acetate attenuates fatty liver and hyperglycemia associated with obesity","volume":"10","author":"Yoshino","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116723_bib232","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99008-2","article-title":"Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis","volume":"11","author":"Bhattacharya","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2024.116723_bib233","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3389\/fphar.2020.00590","article-title":"Repositioning an immunomodulatory drug vidofludimus as a farnesoid X receptor modulator with therapeutic effects on NAFLD","volume":"11","author":"Zhu","year":"2020","journal-title":"Front. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424006044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424006044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:07:06Z","timestamp":1777529226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424006044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":233,"alternative-id":["S0223523424006044"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116723","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116723","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116723"}}